Latest period
$27.50B
YoY change
-198.3%
5Y CAGR
—
Peak year (2022)
$17.25B
Latest annual
−$3.27B
Total Equity history chart for AbbVie (ABBV) from 2010 to 2025
Latest: −$3.27B
Total Equity growth chart for AbbVie (ABBV) from 2010 to 2025
Latest: -198.3%
Total Equity history table for AbbVie (ABBV) from 2010 to 2025
| 2025 | −$3.27B | -198.3% | −$6.59B | ||
| 2024 | $3.33B | -67.9% | −$7.04B | ||
| 2023 | $10.36B | -40.0% | −$6.89B | ||
| 2022 | $17.25B | +12.0% | +$1.85B | ||
| 2021 | $15.41B | +17.8% | +$2.33B | ||
| 2020 | $13.08B | -260.0% | +$21.25B | ||
| 2019 | −$8.17B | -3.2% | +$274.00M | ||
| 2018 | −$8.45B | -265.7% | −$13.54B | ||
| 2017 | $5.10B | +9.9% | +$461.00M | ||
| 2016 | $4.64B | +17.5% | +$691.00M | ||
| 2015 | $3.94B | +126.5% | +$2.20B | ||
| 2014 | $1.74B | -61.2% | −$2.75B | ||
| 2013 | $4.49B | +33.6% | +$1.13B | ||
| 2012 | $3.36B | -71.8% | −$8.57B | ||
| 2011 | $11.93B | -24.0% | −$3.77B | ||
| 2010 | $15.70B | — | — |
- 2025−$3.27B-198.3%
- 2024$3.33B-67.9%
- 2023$10.36B-40.0%
- 2022$17.25B+12.0%
- 2021$15.41B+17.8%
- 2020$13.08B-260.0%
- 2019−$8.17B-3.2%
- 2018−$8.45B-265.7%
- 2017$5.10B+9.9%
- 2016$4.64B+17.5%
- 2015$3.94B+126.5%
- 2014$1.74B-61.2%
- 2013$4.49B+33.6%
- 2012$3.36B-71.8%
- 2011$11.93B-24.0%
- 2010$15.70B—
Total Equity values are taken from AbbVie's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's latest reported total equity is $27.50B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AbbVie (ABBV) most recent annual total equity stands at −$3.27B (2025) – plunged 198.3% year-over-year.
AbbVie total equity plunged from $17.25B in 2022 to −$3.27B in 2025, a 119.0% drawdown.
$17.25B stands as the all-time-high annual total equity, posted in 2022, against a low of −$8.45B during 2018.
AbbVie Total Equity by Year
AbbVie Total Equity 2025: −$3.27B
AbbVie total equity in 2025 was −$3.27B, plunged 198.3% below 2024.
AbbVie Total Equity 2024: $3.33B
2024's total equity for AbbVie came in at $3.33B, plunged 67.9% below 2023.
AbbVie Total Equity 2023: $10.36B
AbbVie posted total equity of $10.36B in 2023, plunged 40.0% below 2022.
AbbVie Total Equity 2022: $17.25B
In 2022, AbbVie reported total equity of $17.25B, grew 12.0% from 2021. This figure represents the highest annual value in the available history.
AbbVie Total Equity 2021: $15.41B
AbbVie total equity in 2021 was $15.41B.
See more financial history for AbbVie (ABBV).
Sector peers by Total Equity
Healthcare peers of AbbVie (ABBV), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $53.41B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation